USE OF RECOMBINANT MYCOBACTERIAL VACCINES FOR MALARIA

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 13635
Amount: $49,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1990
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Medimmune Inc
19 Firstfield Rd, Gaithersburg, MD, 20878
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Vidal F De La Cruz
 (301) 590-2621
Business Contact
Phone: () -
Research Institution
N/A
Abstract
MALARIA, ONE OF THE MOST WIDESPREAD INFECTIOUS DISEASES OF HUMANS, THREATENS ALMOST HALF THE WORLD'S POPULATION. CURRENTLY, THERE ARE AN ESTIMATED 350+ MILLION ACUTE CASES WORLDWIDE EACH YEAR, AND APPROXIMATELY 1 TO 2 MILLION INFANTS AND YOUNG CHILDREN DIE IN AFRICA ALONE BECAUSE OF THE DISEASE. TRADITIONAL METHODS OF CONTROLLING MALARIA WITH INSECTICIDES AND DRUGS HAVE BEEN INADEQUATE. THUS, INCREASED ATTENTION HAS FOCUSED ON DEVELOPING A SAFE AND EFFECTIVE VACCINE AGAINST THE PARASITE. THE OBJECTIVE OF PHASE I IS TO ASSESS THE PROTECTIVE EFFICACY OF IMMUNIZATION WITH RECOMBINANT MYCOBACTERIAL (E.G., BCG) VACCINES CONTAINING THE GENE FROM THE MAJOR SURFACE PROTEIN OF MALARIA SPOROZOITES WITH THE GOAL OF INDUCING PROTECTIVE CELL-MEDIATED IMMUNITY. A PLASMODIUM BERGHEI RODENT MALARIA MODEL WILL BE UTILIZED AS NO RELIABLE ANIMAL MODEL IS CURRENTLY AVAILABLE FOR THE HUMAN MALARIA PARASITES. P. FALCIPARUM AND P. VIVAX. DATA FROM THIS STUDY WILL BE USED TO ESTABLISH PRINCIPLES THAT CAN BE APPLIED TO THE DEVELOPMENT OF NOVEL VACCINE CANDIDATES FOR THE HUMAN MALARIA PARASITES. THIS APPROACH IS OF SPECIAL INTEREST BECAUSE BCG IS CURRENTLY USED FOR VACCINATION IN THE WHO/EXPANDED PROGRAM FOR IMMUNIZATION IN DEVELOPING COUNTRIES WHERE MALARIA IS ENDEMIC.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government